October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.
Promising but early data on PD-1 x CTLA-4 bispecifics from Macrogenics and Akeso add further weight to this approach.